Treatment options in localised and metastatic renal cell carcinoma

被引:0
作者
Berger, A. P. [1 ]
Hobisch, A. [1 ]
机构
[1] Innsbruck Med Univ, Gen Hosp Feldkirch, Dept Urol, Acad Teaching Hosp, Carinagasse 47, A-6800 Feldkirch, Austria
关键词
Renal cell carcinoma; targeting therapy; antiangiogenic therapy; nephrectomy;
D O I
10.1007/s12254-008-0055-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal cell cancer (RCC) accounts for 2% of all malignancies. RCC shows a rising incidence and overall mortality is the highest among all urologic malignancies. In localised disease, radical cancer surgery remains the only potential curative treatment option. Indications for nephron-sparing surgery include renal tumours 4 cm or less in diameter and patients with solitary kidneys or bilateral synchronous RCC. Nephron-sparing surgery is also recommended in patients with conditions that might lead to impaired kidney function later on. In metastatic RCC (mRCC), cytoreductive surgery followed by the immunotherapy has proven to be a mainstay in patients with a good performance status. Chemotherapy has no role in the treatment of mRCC. Pharmacological treatment of mRCC has significantly changed in the last months due to the approval of targeted therapies such as sunitinib, sorafenib, bevacizumab or temsirolimus, which have largely replaced immunotherapy. Immunological therapy has been the standard of care in the treatment of mRCC in the last decade. Sequencing therapy and combination of different treatment modalities may further increase therapeutic options in the future. The purpose of the following short review is to summarize the contemporary treatment options in localised and metastatic RCC.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 50 条
[31]   A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options [J].
Bellmunt, Joaquim ;
Eisen, Tim ;
Szczylik, Cezary ;
Mulders, Peter ;
Porta, Camillo .
BJU INTERNATIONAL, 2011, 107 (08) :1190-1199
[32]   Safety of available treatment options for renal cell carcinoma [J].
Derosa, Lisa ;
Albiges, Laurence ;
Massard, Christophe ;
Loriot, Yohann ;
Fizazi, Karim ;
Escudier, Bernard .
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) :1097-1106
[33]   Sequential therapy and new therapy options for metastatic renal cell carcinoma [J].
Hornig, M. ;
Gruenwald, V. .
ONKOLOGE, 2015, 21 (01) :43-+
[34]   Treatment of metastatic renal cell carcinoma and renal pelvic cancer [J].
Tanji, Nozomu ;
Yokoyama, Masayoshi .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (03) :331-338
[35]   Treatment of metastatic renal cell carcinoma and renal pelvic cancer [J].
Nozomu Tanji ;
Masayoshi Yokoyama .
Clinical and Experimental Nephrology, 2011, 15 :331-338
[36]   Treatment options for renal cell carcinoma in renal allografts: a case series from a single institution [J].
Swords, Darden C. ;
Al-Geizawi, Samer M. ;
Farney, Alan C. ;
Rogers, Jeffrey ;
Burkart, John M. ;
Assimos, Dean G. ;
Stratta, Robert J. .
CLINICAL TRANSPLANTATION, 2013, 27 (02) :E199-E205
[37]   Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma [J].
Obeng-Kusi, Mavis ;
Kreutzfeldt, Jordyn J. ;
Estrada-Mendizabal, Ricardo J. ;
Choi, Briana M. ;
Abraham, Ivo ;
Recio-Boiles, Alejandro .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (02) :32e1-32e8
[38]   Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma [J].
Miller, K. ;
Bergmann, L. ;
Gschwend, J. ;
Keilholz, U. .
AKTUELLE UROLOGIE, 2011, 42 (04) :242-246
[39]   Current Treatment Considerations in Metastatic Renal Cell Carcinoma [J].
Housam Haddad ;
Brian I. Rini .
Current Treatment Options in Oncology, 2012, 13 :212-229
[40]   Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma [J].
Miller, K. ;
Bergmann, L. ;
Jaeger, E. ;
Jakse, G. ;
Wirth, M. ;
Keilholz, U. .
AKTUELLE UROLOGIE, 2009, 40 (01) :27-30